MRI can detect 90 percent of breast cancers
the ONA take:
A recent study has determined that approximately 90 percent of breast cancers can be diagnosed via magnetic resonance imaging (MRI).
The research team, based at the University Department of Radiology and Nuclear Medicine at the MedUni Vienna, in cooperation with the University Department of Gynaecology and Obstetrics and the Clinical Institute of Pathology, compared results from mammography, ultrasound, and MRI testing.
Records from 559 women with breast cancer were reviewed, which totaled 1,365 screening tests. Ultrasound alone was not useful in detecting the breast cancer, whereas MRI clearly established the presence of breast cancer approximately 90 percent of the time.
The addition of mammography screen to MRI increased detection by approximately 5 percent. Screening results for the various methods to detect benign lesions was comparable. Results were also unaffected by the variables of gene mutation, age of the patient, or degree of breast density.
Study leaders Thomas Helbich and Christopher Riedl feel the results should serve as a call for increased use of NRI for breast cancer detection, and that high-risk individuals with a family history of breast cancer should opt for yearly MRI testing.
The current EU ratio is 10 MRI scanners per one million inhabitants, a somewhat low ratio if MRI testing were to be increased.
Study findings were published in the Journal of Clinical Oncology.
A recent study has determined that approximately 90 percent of breast cancers can be diagnosed via MRI.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|